Thirty years ago, the links between cholesterol and coronary disease were controversial. This is no longer the case, but attention has remained riveted on cholesterol - even though there is more and more evidence pointing to fatty acids as the prime culprits responsible for the common atherogenic dyslipoproteinemias. This book addresses the fatty acid side of the ledger and covers all the common atherogenic dyslipoproteinemias, putting them in metabolic and clinical context. This includes the relationships that have recently emerged between fatty acid metabolism and the inflammatory and prothrombogenic molecules. Understanding these relationships has important consequences for therapy and detailing how apoB changes therapy is a key objective. The author writes in an accessible style, using the open language and form that characterizes much of his previous scientific writing, and has succeeded in presenting hard core science in a form that can be understood and appreciated by clinicians.